Influence of Esmolol on a Closed-Loop Anesthesia System

• Status: Terminated
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

Main objective is to evaluate the sparing effect of esmolol on the required doses of propofol and remifentanil

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hopital Foch
• Treatments: Esmolol; Propofol; Remifentanil

Criteria

Inclusion Criteria:

• male patients scheduled for a general anesthesia

Exclusion Criteria:

• age lower than 18 years

• allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine, or to a myorelaxant or to an excipient,

• any other history of anaphylactic reaction,

• hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,

• hypersensibility to esmolol or to an excipient,

• history of central nervous system disease,

• patients receiving a psychotropic treatment or an agonist-antagonist opiate,

• hypovolemic patients,

• patients receiving a cardio-vascular treatment,

• patients with a pacemaker,

• expected bleeding more than 20% of the blood volume,

• simultaneous general and loco-regional anesthesia,

• patients suffering from asthma, COPD, trouble of the heart rhythm or conduction, cardiac insufficiency, cardiogenogenic shock, Prinzmetal syndrome, pheochromocytoma,

• patients with a heart rate less than 50/min and/or an arterial hypotension,

• neurosurgical act or any other which precludes an adequate positioning of the bispectral electrode.